Content overview :
1.5 hour sessions during 2022 that will be case study-driven, with pre-reads sent in advance, and a bias towards interactive discussions and Q&A during each session
The following key questions will be addressed:
- What do we mean by “market access”? (note we will focus on health technology assessment (HTA), funding and reimbursement issues, not regulatory issues such as CE marking, EMA or FDA approvals)
- Are companies understanding and thinking about market access early enough in their product development processes?
- What is the depth of companies’ understanding of market access issues?
- What resources do companies have available to address market access over the development life-cycle?
- How much scope is there to address market access sooner rather than later?
- What/how should companies prioritise to have the greatest impact?
is the Founder and Principal of InnAxx Consulting, based in Lausanne, where he has lived and worked for 22 years. He works with a select group of multinational healthcare companies, industry associations, startup companies, NGOs and academic professionals that are bringing innovative approaches to global health, healthcare delivery and healthy aging. Herb has had a diverse 34-year international career with global leadership roles in multinational enterprises, including Swiss-based roles with multinational corporations Amgen (biotechnology) and Medtronic (medical technology) where he built international market access, healthcare policy, government affairs, strategic philanthropy, corporate communications and law functions.
is the Founder and Principal of F+R Services, based in Zurich, which helps companies develop and implement tailored market access strategies for the Swiss market. She has over 25 years’ experience in the Swiss healthcare sector, including working with private and public hospitals, medical group practices and the medical device industry, including 12 years with Medtronic’s Swiss affiliate in Bern.She also acts as a mentor for Market Access at the Diabetes (DCB) open Innovation Challenge in Berne.Mayella is an experienced market access and reimbursement professional who brings a deep knowledge of the Swiss healthcare system, including inpatient and outpatient tariff systems.
is the Director of Ceelos Consulting, which provides strategic advice and practical solutions in health economics, market access and pricing for the life sciences industry. He is also a member of the Technology Appraisal Committee of the National Institute of Health and Care Excellence (NICE) which conducts health technology assessments and makes recommendations on funding of new health technologies for the UK national health system. Previously Giles spent 2 years as Health Economics and Outcomes Research (HEOR) Director at Vitaccess and 4 years at PRMA Consulting leading a variety of health economics and market access projects for biopharmaceutical and medtech clients. He is based in Annecy (FR) and previously lived for ten years in the Lac Leman area, including working for Medtronic in Tolochenaz (Morges) from 2008-11.
09.06.2022 | Online
Save the date Workshop Medtech Market Access Series
Part 2 :The patient perspective: identifying and communicating patient needs.
22.09.2022 | Online
Part 3 : The product perspective: demonstrating value with evidence.
17.11.2022 | At Biopôle
Part 4: The health system perspective: stakeholder mapping, public policy, funding and advocacy.